Related Experiment Video
Updated: Jan 27, 2026
10:11
Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies
Published on: October 22, 2014
19.6K
Switching Between β-Blockers: An Empiric Tool for the Cardiovascular Practitioner
Thomas M Roston1, Doson Chua2, Elaine Lum2
1Division of Cardiology, St Paul's Hospital and Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
The Canadian Journal of Cardiology
|April 3, 2019
Summary
Switching beta-blockers is common for cardiovascular patients due to changing health or side effects. This guide offers a practical approach for cardiologists to manage beta-blocker transitions effectively.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers are crucial for cardiovascular disease management.
- Clinical benefits and indications vary among beta-blocker agents.
- Patient status changes necessitate switching beta-blockers, but guidelines are lacking.
Purpose of the Study:
- To present a practical approach for switching between beta-blocker medications.
- To address the lack of specific guidelines for beta-blocker transitions.
- To provide recommendations for common challenges in beta-blocker therapy.
Main Methods:
- Consideration of drug interchangeability for specific cardiovascular indications.
- Evaluation of rationales for switching beta-blocker agents.
- Analysis of initial dose/frequency adjustments and target/maximal dose differences.
Main Results:
- A framework for selecting alternative beta-blockers based on indication.
- Guidance on managing medication intolerance and acute illness adjustments.
- Practical strategies for dose titration and comparison of different beta-blockers.
Conclusions:
- A practical approach to switching beta-blockers can improve patient care.
- Addressing common challenges in beta-blocker therapy is essential.
- Standardized guidance is needed for cardiologists managing beta-blocker transitions.
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
1.5K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.5K
01:28Antihypertensive Drugs: Types of β-Blockers
1.6K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.6K
01:22Heart Failure Drugs: β-Blockers
850
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
850
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.2K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.2K
01:17Antihypertensive Drugs: Action of β1 Blockers
2.0K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.0K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.6K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.6K